One of the most damaging legacies of diabetes is written into the lining of the blood vessels themselves. Chronic high blood sugar slowly erodes the endothelium, the delicate single-cell layer that governs vascular tone, blood clotting, and the exchange of nutrients between blood and tissue. This endothelial dysfunction is the common soil in which heart attacks, strokes, kidney failure, and limb amputations take root, yet the molecular chain of events that connects elevated glucose to failing vessels has remained only partially mapped. A new study published in Cellular and Molecular Life Sciences by Yann Salemkour, Olivia Lenoir, and colleagues now identifies a surprising culprit in this chain: a family of calcium-activated proteases called calpains, whose overactivation under hyperglycemic conditions appears to sabotage one of the cell’s most essential quality-control systems.
The system in question is autophagy, the cellular recycling program that engulfs damaged proteins and organelles in double-membraned vesicles and delivers them to lysosomes for degradation. Within mitochondria, a specialized form of this process, known as mitophagy, selectively removes dysfunctional mitochondria before they leak reactive oxygen species and trigger cell death. When autophagic flux runs smoothly, the endothelium stays clean and energetic. When it stalls, debris accumulates, mitochondria fragment into dysfunctional shards, and the cell’s metabolic machinery begins to misfire. The French-led research team, working across institutions in Paris and Angers with collaborators in Japan, set out to determine whether calpains, enzymes best known for degrading structural proteins under stress, might be the hidden hand jamming this recycling machinery in diabetes.
The investigators began with human umbilical vein endothelial cells and primary lung endothelial cells exposed to high glucose concentrations in the laboratory. Under these diabetic-mimicking conditions, they observed a clear activation of calpains, detectable through the characteristic cleavage of their substrates. More importantly, they documented a full-blown autophagic flux blockade. The cargo receptor protein SQSTM1, also known as p62, accumulated to abnormal levels because it was no longer being efficiently cleared, while expression of LC3B, the lipidated protein that decorates autophagosomal membranes, was reduced. In practical terms, the conveyor belt carrying cellular waste to the lysosome had ground to a halt, and the mitochondria within these cells responded by fragmenting, losing the elongated, interconnected network architecture that healthy endothelial cells depend upon for efficient energy production.
To test whether calpains were truly the drivers of this collapse rather than innocent bystanders, the team deployed two complementary strategies. The first was pharmacological: small-molecule inhibitors that block calpain enzymatic activity. The second was genetic: overexpression of calpastatin, the endogenous protein that naturally inhibits calpains and serves as the body’s built-in brake on these proteases. Remarkably, both approaches produced the same result. Blocking calpain activity restored autophagic flux, allowing SQSTM1 to be cleared and LC3B-mediated autophagosome formation to resume, and it preserved the mitochondrial network, preventing the pathological fragmentation that hyperglycemia would otherwise induce. The convergence of drug-based and gene-based evidence strengthens the causal argument considerably, ruling out the possibility that the inhibitor was working through some unrelated off-target pathway.
To understand the broader consequences of calpain inhibition at the level of gene expression, the researchers performed transcriptomic profiling of endothelial cells subjected to high glucose with and without calpain blockade. The results revealed that calpain inhibition counteracted several major hyperglycemia-driven transcriptional programs. Among the most prominent were pathways governing oxidative phosphorylation, the mitochondrial process that generates most of the cell’s ATP; reactive oxygen species signaling, which spirals dangerously upward when mitochondria fail; and the unfolded protein response, a stress program activated when the endoplasmic reticulum is overwhelmed. In other words, restraining calpains did not merely patch one leak in the diabetic endothelium but appeared to rebalance an entire constellation of stress responses that high glucose had pushed out of alignment.
The mechanistic picture that emerges is elegant in its simplicity. Hyperglycemia floods endothelial cells with calcium signals and oxidative stress, which overactivate calpains. These proteases then disrupt the autophagy-mitophagy axis, either by directly degrading components of the autophagic machinery or by damaging the lysosomal system that completes the degradation process. With mitophagy impaired, damaged mitochondria escape removal, fragment, and pour out reactive oxygen species, which in turn inflict further damage on proteins and organelles, creating a self-reinforcing cycle of dysfunction. Calpain inhibition breaks this vicious cycle at its upstream point, restoring the cell’s capacity for self-renewal before the downstream damage becomes irreversible. This positions calpains not as one among many secondary casualties of diabetes but as a genuine regulatory node in the pathogenesis of vascular disease.
Crucially, the team did not confine their work to cell culture dishes. They extended their findings into living animals, using mouse models of diabetes to ask whether calpain inhibition could preserve vascular function in the intact organism. The answer was affirmative: treatment that restrained calpain activity preserved vascular reactivity in diabetic mice, the ability of blood vessels to dilate and constrict appropriately in response to physiological cues. This functional rescue is the metric that matters most for translational relevance, because endothelial dysfunction in patients is measured precisely by the loss of this dynamic responsiveness, whether in the coronary arteries feeding the heart or the glomerular capillaries sustaining the kidneys. The study also made use of mitoQC reporter mice, a sophisticated genetic tool developed in Ian Ganley’s laboratory at the University of Dundee, which allows mitophagy to be visualized directly in tissues, providing in vivo confirmation of the cellular findings.
The implications for diabetic patients are significant but must be weighed with appropriate caution. Calpains have been implicated in a wide range of physiological processes, including platelet activation, muscle remodeling, and neuronal function, which means that systemic calpain inhibition carries potential risks that will need careful evaluation. The study’s use of both pharmacological inhibitors and calpastatin overexpression suggests that even partial or tissue-targeted modulation of calpain activity might be sufficient to confer vascular protection, which could open the door to therapeutic strategies that maximize benefit while limiting collateral effects. It is also worth noting that the work was supported by the Société francophone du diabète, Laboratoire Servier, and the EFSD/Novo Nordisk Programme for Diabetes Research in Europe, reflecting a serious institutional commitment to translating basic endothelial biology into clinical applications.
What makes this research resonate beyond the diabetes field is its contribution to a growing appreciation of autophagy as a master regulator of vascular health. Endothelial cells are among the longest-lived cells in the body, exposed continuously to mechanical forces, metabolic fluctuations, and inflammatory insults over decades. Their survival depends on relentless intracellular housekeeping, and any mechanism that compromises that housekeeping, whether it is a protease gone rogue or a lysosome gone sluggish, accelerates vascular aging. By identifying calpain overactivation as a specific and druggable point of failure in the diabetic endothelium, Salemkour, Lenoir, and their colleagues have added a precise new entry to the molecular map of diabetic vascular disease, and they have demonstrated that the map can be redrawn toward health with the right molecular intervention.
The road from a mouse study to a bedside therapy is long, and the authors themselves frame calpain inhibition as a promising strategy rather than a finished treatment. Nevertheless, the convergence of cellular mechanistics, transcriptomic breadth, and intact-animal functional data makes this one of the more complete preclinical demonstrations in the endothelial autophagy literature. For the hundreds of millions of people worldwide living with diabetes, whose risk of cardiovascular death is roughly doubled compared with the general population, the finding that a single enzymatic family stands between high glucose and the collapse of mitochondrial quality control offers something genuinely new: a target that, if safely inhibited, could preserve the vessels that diabetes slowly destroys. The next chapter will be written in the clinic, but the molecular groundwork has now been firmly laid.
Subject of Research: The role of calpain-mediated autophagy and mitophagy blockade in diabetic endothelial dysfunction
Article Title: Calpain inhibition prevents high-glucose-induced autophagy blockade and mitochondrial fragmentation in endothelial cells and preserves vascular functions in diabetic mice
Article References: Salemkour, Y., Dionet, L., Vessieres, E., Saito, R., Le Gall, M., Letavernier, E., Henrion, D., Tharaux, P.-L., & Lenoir, O. (2026). Calpain inhibition prevents high-glucose-induced autophagy blockade and mitochondrial fragmentation in endothelial cells and preserves vascular functions in diabetic mice. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06433-5
Image Credits: AI Generated
DOI: 10.1007/s00018-026-06433-5
Keywords: diabetes, endothelial dysfunction, calpain, autophagy, mitophagy, mitochondria, hyperglycemia, vascular function, calpastatin, oxidative stress, endothelium, diabetic complications
